Breast malignancy in female-to-male transsexuals: systematic review, case report, and recommendations for screening

Anne C. Fledderus a, *, H. Antoine Gout a, Aernout C. Ogilvie b, Dorothea K.G. van Loenen c

Article info

Article history:
Received 8 May 2020
Received in revised form 25 June 2020
Accepted 26 June 2020
Available online 2 July 2020

Keywords:
Transsexual
Transgender
Breast malignancy
Breast cancer
Breast neoplasm
Hormone therapy
Testosterone

Abstract

Background: Female-to-male (FtM) transsexuals may use testosterone therapy for masculinization, which potentially influences the risk of breast cancer development. Guided by our case report, we aimed to investigate the evidence regarding the risk of testosterone therapy on breast malignancy in female-to-male transsexuals and evaluate breast cancer screening in this subgroup.

Methods: We conducted a systematic literature search according to the PRISMA checklist in June 2020 in PubMed/MEDLINE and Ovid/EMBASE. Reference lists of included articles were screened to find additional articles that met the inclusion criteria. All cohort studies and case reports evaluating breast cancer in FtM transsexuals after testosterone therapy were included.

Results: We found 23 cases of FtM transsexuals who developed breast cancer after testosterone therapy, including our own case. Moreover, we evaluated ten retrospective cohort studies investigating breast malignancy in the transsexual population. The cohort studies showed no elevated risk in FtM transsexuals compared to natal women. Including our own case, nine cases were described in which breast malignancy was incidentally found during routine histological examination after mastectomy. High-level evidence for a correlation between testosterone therapy and breast malignancy is missing.

Conclusion: Few cases are described of FtM transsexuals with breast malignancy. However, cases such as these make physicians aware of the possibility of breast cancer in FtM transsexuals. Radiological screening of FtM transsexuals for breast cancer prior to mastectomy and histological screening of the mammalian tissue after mastectomy should be considered; physicians should decide together with every individual FtM transsexual if screening is necessary.

© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Contents

Background ................................................................. 93
Methods ................................................................. 93
Case report ............................................................... 93
Case report ............................................................... 93
Results ................................................................. 93
Quality assessment .................................................. 94
Discussion ............................................................... 95
Conclusion ............................................................... 97
Disclosure statement ............................................... 97
Funding ................................................................. 97
Ethical approval ....................................................... 98
Background

Breast cancer is the most common malignancy and the most frequent cause of death from cancer in natal women [1]. The risk of developing breast cancer in female-to-male (FtM) transsexuals is unknown [2]. FtM transsexuals could be at extra risk due to the testosterone therapy they may receive for masculinization [3,4]. The associations between testosterone and breast cancer are debated in the literature. Proliferative effects of testosterone on breast cancer are described, but antiproliferative effects are suggested as well [5]. It is unclear if FtM transsexuals with a history of testosterone use have a higher or lower risk of developing breast cancer [2]. We aimed to provide an insight into the reported number of FtM transsexuals developing breast cancer after testosterone therapy by systematically reviewing the literature and evaluating the evidence regarding associations between testosterone therapy and breast cancer. In addition, we report a case of an FtM transsexual with a history of testosterone use, in whom a neoplasm was found in the breast tissue after mastectomy.

Methods

We conducted a systematic review, reported according to the PRISMA checklist [6]. A search was performed in June 2020 in PubMed/MEDLINE and Ovid/EMBASE (Appendix 1). Furthermore, reference lists of included articles were screened to find additional articles that met the inclusion criteria. All articles evaluating breast cancer in FtM transsexuals after testosterone therapy were deemed eligible, including case reports, case series, cohort studies, and case-controlled studies. Two reviewers (ACF, HAG) independently screened titles and abstracts. Full texts of potentially eligible studies were critically reviewed to assess eligibility. Disagreement on inclusion was resolved through discussion.

Data extraction was performed in duplicate by two independent reviewers (ACF, HAG). The following data was extracted from the FtM transsexual cases with testosterone use developing breast malignancy: age of diagnosis of breast malignancy, whether this diagnosis was prior to or after subcutaneous mastectomy, family history of breast malignancy, testosterone use in years, tumor type, BRCA gene status, hormone receptor status. The Joanna Briggs Institute’s critical appraisal tools were used to perform a quality assessment of the included studies [7]. We evaluated every case individually with the risk of bias tool for case reports. The cohort study risk of bias tool was used to evaluate the evidence regarding the relation between testosterone use and breast cancer development investigated by the included cohort studies. We did not exclude articles based on their quality, as we aimed to give an overview of available evidence. Data synthesis was performed by using descriptive statistics.

Case report

We reported a case of an FtM transsexual with breast neoplasm after testosterone use. The casereport was reported according to the CARE checklist for case reports [8].
subjects. Fourteen of the tumors were described to be of ductal origin. Estrogen and progesterone receptor status were reported in twenty and nineteen cases respectively. Estrogen was positive in seventeen, negative in three, and progesterone was positive in thirteen and negative in six. The HER2 receptor was reported in thirteen cases. It was positive in seven and negative in six. The androgen receptor was tested in six subjects and positive in five and negative in one. One triple-negative breast cancer was reported.

We found ten retrospective cohort studies evaluating breast cancer in FtM transsexuals with a history of testosterone therapy. In five of these cohort studies, no cases of breast cancer were found [11–15]. These cohort studies, however, were relatively small: respectively 293, 112, 133, and 56 FtM transsexuals with hormone therapy [11–15]. One of these studies only found a case of breast malignancy in the group of FtM transsexuals not using testosterone (n = 130), concluding that there is no elevated risk for individuals using testosterone compared to those not using testosterone [15]. A study with 1579 American veteran FtM transsexuals found seven FtM transsexuals with breast cancer, whereas only one was documented to use testosterone prior to diagnosis [16]. Three cohort studies including 795, 96, and 283 FtM transsexuals receiving testosterone all found one subject with breast malignancy or pre-malignancy in their cohort [17–19]. A recent Dutch study evaluated the incidence of breast cancer in the FtM transsexual population in their clinical center [20]. In their population of 1229 FtM transsexuals, four cases of invasive breast cancer were diagnosed [20]. According to the findings of this study, this FtM transsexual population has a lower risk of developing breast cancer compared to Dutch natal women, but a higher risk compared to Dutch natal men [20]. Note that the studies by Goren et al. (2013 & 2015) [17,21] were performed in the same clinical center as the recent Dutch study (2019) [20]. Two of the four cases described by this Dutch study might have been the same as those in Goren et al. (2013 & 2015) [17,21].

Quality assessment

Fig. 3 (case reports) and Fig. 4 (cohort studies) show the results of the quality assessment by means of the two JBI tools. In Appendix 2, the evaluations of every individual case report and cohort study are shown. Three cohort studies formed a control group [15,18,19] and six studies collected data of cancer incidence in the general population as a control [11,13,14,16,17,20]. One study did not make use of a control group [12]. Six studies stratified patients based on age and sex [11,13,14,16,17,20]. Several confounding factors were reported, including a history of mastectomy [12, 13, 15, 18, 19], family history [19], bodyweight/BMI [18, 19, 34], smoking status [14, 19, 34], and alcohol use [19], but none corrected for these in the analyses. The JBI and CARE checklist recommend presenting the
Discussion

Data on breast cancer in FtM transsexuals with a history of testosterone use is limited to the cases described in Table 1. The incidence of breast cancer cases described in the FtM transsexuals cohort studies is shown to be significantly lower than the breast cancer incidence in natal women [16,17,20]. Due to the low level of evidence (case reports) and high risk of bias of the included cohort studies, it is not possible to conclude a correlation between hormone therapy and the development of breast cancer.

All cohort studies and case reports did not report screening for cancer in advance of testosterone therapy, which complicates the evaluation of its potential causal relationship with cancer. Whether follow-up was sufficiently long enough (range: < 1 yr - > 30 yr) could not be determined for any study, since the course of cancer development in these patients is still unclear. Moreover, younger patients may demand a longer follow-up, since their baseline cancer risk is lower than those of older patients. Confounders were poorly described and none was appropriately corrected for in the analysis. The most important confounder for investigating the effect of testosterone on breast malignancy is a history of mastectomy. The lower incidence of breast cancer found in the studies can be attributed to the performed mastectomies. Mastectomy is often the first and only step of gender reassignment surgery of FtM transsexuals [35]. After mastectomy with nipple reimplantation, the risk of breast cancer in an FtM is reduced by nearly 90% [10].

Nonetheless, breast tissue is often not radically removed when the indication for a subcutaneous mastectomy is sex reassignment for FtM transsexuals [36]. This may explain the seven rare cases describing breast cancer development after mastectomy [20,23,24,28,30]. The 23 subjects with breast cancer were relatively young (mean age 42 years). A large number of older FtM transsexuals may have undergone a mastectomy, which decreases the risk of malignancy in older individuals [10,24]. The majority of subjects had an invasive tubular carcinoma, which is in line with the general population; an estimated 76% of the invasive tumors are of tubular origin [37].

In the literature, two theories suggest an association between breast cancer development and testosterone therapy. The first theory suggests an increased risk of breast cancer because testosterone is aromatized into estradiol, which in turn is associated with breast tumor growth [28,38]. Associations between elevated endogenous testosterone levels and breast cancer development have been shown by several studies [39–41]. It has been suggested that higher blood plasma levels of androgens can specifically increase the risk of hormone-receptor-positive breast cancer [42–45]. Furthermore, one study showed that androgens could decrease the risk of developing receptor-negative breast cancer [46]. This could explain the relatively high presence of hormone-positive breast cancer found in our subjects and relatively low number of individuals with hormone negative breast cancer. HER2-positive tumors were reported in 37% (7/19) of the invasive carcinomas. In the general female population, HER2-positive tumors are estimated to be 15% of invasive carcinomas [47]. However, the individuals included in our study were relatively young and younger individuals with breast cancer tend to have a higher incidence of HER2-positive breast cancer [48].

In contrast to the first theory, the second suggests that testosterone reduces breast cancer risk [49, 50]. One study showed a lower incidence of breast cancer in women using testosterone therapy [50]. A preclinical study supports this theory, showing both a proliferative effect of androgens and an antiproliferative effect of...
androgens mediated by the androgen receptor [5]. Moreover, testosterone use reduces breast tissue density [51], and dense breast tissue has been shown to be a risk factor for breast malignancy [52]. Another risk factor for breast malignancy is a high number of menstruation cycles and high lifetime menstruation activity [53]. Testosterone could have an antiproliferative effect by suppressing the menstruation cycles in FtM transsexuals [13]. The ‘Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People’ state that there is no increased risk of breast cancer for individuals treated with testosterone [4].

Breast cancer screening prior to mastectomy was not performed in our case. Luckily, the neoplasm was completely removed after...
However, when breast tumors are discovered before mastectomy, tumors can be removed more precisely. This requires routine breast cancer screening before every mastectomy. Nevertheless, routine screening in young individuals might be unnecessary since their overall low risk of breast cancer [54,55]. Screening could then lead to false-positive results, causing stress and unnecessary radiation, costs, and therapy [54]. Moreover, mammography can be stressful for FtM transsexuals since the test is not consistent with their male gender identity [56].

As it is unclear whether FtM transsexuals without mastectomy have a higher or lower risk of developing breast cancer compared to natal women, it is unclear at what age screening for breast cancer would be effective. Two studies recommend population screening of FtM transsexuals according to current guidelines of natal women [55–58]. One study additionally recommends shared decision-making in order that FtM transsexuals can decide together with their physicians if they need screening, after having received information about the harms and benefits of screening [59]. Another study additionally recommends screening transsexuals with a history of five years of hormone therapy [60]. Both these recommendations can likely be used to determine if it is necessary to screen prior to mastectomy.

Including our own case, in nine cases the breast tumor was incidentally found by routine histological examination after mastectomy (Table 1). Routine histological examination of the breast tissue after every mastectomy is recommended in the literature [18,61]. This is recommended for reduction mammoplasty as well [62]. However, both these conclusions are based on only a few cases. It is difficult to make evidence-based recommendations based on the current literature. Routine histopathological screening after mastectomy could have relevant clinical consequences for at least the individuals who are at increased risk of developing breast cancer. Factors such as increasing age or positive family history could be taken into consideration. National guidelines can be used to assess which individuals are at increased risk [55,63].

Prior to testosterone therapy for masculinization, our subject used anabolic-androgenic steroids, which are steroids that include synthetic substances that have similar effects as testosterone. We found no literature describing an association between the use of anabolic-androgenic steroids and an elevated risk of breast cancer development.

**Conclusion**

Including our own case, we described 23 cases of FtM transsexuals developing breast cancer after testosterone therapy. Cases such as these make physicians aware of the possibility of breast cancer development in this population. Breast cancer screening of FtM transsexuals prior to mastectomy and histological examination of the mammalian tissue after mastectomy could be considered. In consultation with every individual FtM transsexual, physicians can decide if screening before and after mastectomy is necessary.

**Disclosure statement**

The authors have no other financial or personal relationships relevant to this study to disclose. No funding was received for this article. There are no conflicts of interest to disclose.

**Funding**

There was no funding for this study.
Ethical approval

The patient gave verbal informed consent for this study. Formal consent is not required for the literature study.

Declaration of competing interest

The authors declare that they have no conflict of interest.

Appendix 1. Search

Pubmed/MEDLINE search:
(Transgender Persons [Mesh] OR transsexualism [Mesh] OR transgender* [tiab] OR transsexual* [tiab] OR intersex* [tiab] OR female-to-male [tiab] OR FtM transsexual [tiab])
AND
(Breast Neoplasm [Mesh] OR breast cancer [tiab] OR breast malignancy [tiab] OR breast tumor* [tiab] OR breast carcinoma [tiab] OR mamma carcinoma [tiab] OR mammary neoplasm [tiab] OR mammary cancer [tiab])
AND
English [la]
NOT
(Clinical Conference [pt] OR Consensus Development Conference [pt] OR Consensus Development Conference, NIH [pt] OR Meeting Abstract [pt])

Ovid/EMBASE search:
1. exp transgender/
2. exp transsexualism/
3. exp intersex/
4. 1 or 2 or 3
5. (transgender* or transsexual* or intersex* or female-to-male or FtM transsexual) [ti, ab, kw.]
6. 4 or 5
7. exp breast tumor/
8. (breast cancer or breast malignancy or breast tumor* or breast carcinoma or mamma carcinoma or mammary neoplasm or mammary cancer) [ti, ab, kw.]
9. 7 or 8
10. 6 and 9
11. limit 10 to conference abstract status
12. 10 not 11
13. limit 12 to english language

Appendix 2. Risk of bias assessment of case reports and cohort studies

Since we predetermined not to exclude studies based on their quality, we answered "yes" for the 'overall judgment' of each study. Risk of bias for every individual case report:

| Study          | D1 | D2 | D3 | D4 | D5 | D6 | D7 | D8 | Overall |
|----------------|----|----|----|----|----|----|----|----|---------|
| Bagothri et al. (2018) | +  | x  | +  | +  | x  | +  | x  | x  | +      |
| Burcombe et al. (2003)   | +  | x  | +  | +  | +  | x  | +  | x  | +      |
| Chotsi et al. (2019)     | +  | x  | +  | +  | x  | x  | x  | +  | +      |
| Elsman et al. (2019)     | +  | x  | +  | +  | x  | x  | x  | +  | +      |
| Furlidus et al. (2019)   | +  | x  | +  | +  | +  | +  | x  | +  | +      |
| Gooren et al. (2015) (age 41) | +  | x  | +  | +  | +  | +  | +  | +  | +      |
| Gooren et al. (2015) (age 48) | +  | x  | +  | +  | +  | +  | +  | +  | +      |
| Katayama et al. (2016)   | +  | x  | +  | +  | +  | +  | +  | +  | +      |
| Light et al. (2020)      | +  | x  | +  | +  | +  | +  | +  | +  | +      |
| Nikolic et al. (2012)    | +  | x  | +  | +  | +  | +  | x  | +  | +      |
| Shao et al. (2011) (age 27) | +  | x  | +  | +  | x  | +  | +  | +  | +      |
| Shen et al. (2011) (age 33) | +  | x  | +  | +  | +  | +  | +  | +  | +      |
| Tantiri et al. (2019) (age 33) | +  | x  | +  | +  | +  | +  | +  | +  | +      |
| Tantiri et al. (2019) (age 36) | +  | x  | +  | +  | +  | +  | +  | +  | +      |
| Treskova et al. (2016)   | +  | x  | +  | +  | +  | +  | x  | +  | +      |

| D1: Were patient's demographic characteristics clearly described? |
| D2: Was the patient's history clearly described and presented as a timeline? |
| D3: Was the current clinical condition of the patient on presentation clearly described? |
| D4: Were diagnostic tests or assessment methods and the results clearly described? |
| D5: Was the intervention(s) or treatment(s) clearly described? |
| D6: Was the post-intervention clinical condition clearly described? |
| D7: Were post-intervention clinical condition outcomes clearly identified and described? |
| D8: Does the case report provide takeaway lessons? |

Judgement: 
- Yes
- No
- Not applicable
Risk of bias for every individual cohort study:

References

[1] Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Canc 2019;144(8):1941–53.
[2] Feldman J, Safer J. Hormone therapy in adults: suggested revisions to the sixth version of the standards of care. Int J Transgenderism 2009;11(3):146–82.
[3] Hembree WC, Cohen-Kettenis PT, Gooren LJ, Hannema SE, Meyer WJ, Murad MH, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metabol 2017;102(11):3869–903.
[4] Coleman E, Bockting W, Botzer M, Cohen-Kettenis P, DeCuypere G, Feldman J, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgenderism 2012;13(4):165–232.
[5] Brettes J-P, Mathelin C. Dual effects of androgens on mammary gland. Bull Canc 2008;95(5):495–502.
[6] McNinnes MD, Mehta D, Thoms BD, McGrath TA, Bossuyt PM, Clifford T, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. Jama 2018;319(4):388–96.
[7] Moola S, Munz Z, Tuñanaru C, Aromataris E, Sears K, Sfetcu R, et al. Joanna Briggs Institute reviewer’s manual. Chapter 7: systematic reviews of etiology and risk. The Joanna Briggs Institute; 2017. Available from: https://reviewersmanual.joannabriggs.org/.
[8] Riley DS, Barber MS, Kienle GS, Aronson JK, von Schoen-Angerer T, Tugwell P, et al. CARE guidelines for case reports: explanation and elaboration document. J Clin Epidemiol 2017;89:218–35.
[9] Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2020;18(4):452–78.
[10] Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold P, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340(2):77–84.
[11] van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol 1997;47(3):337–42.
[12] Grynberg M, Fanchin R, Dubost G, Colau JC, Bremont-Weil C, Fydrich R, et al. Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. Reprod Biomed Online 2010;20(4):533–8.
[13] Dhjene C, Lichtenstein P, Boman M, Johannson AL, Langstrom N, Landen M. Long-term follow-up of transsexual persons undergoing sex reassignment surgery: cohort study in Sweden. PloS One 2011;6(2):e16885.
[14] Asscheman H, Giltay EJ, Megens JA, de Roos WP, van Trotsenburg MA, Gooren LJ. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2011;164(4):635–42.
[15] Eismann J, Heng YJ, Fleischmann-Rose K, Tobias AM, Phillips J, Wulf GM, et al. Breast cancer in a female to male transgender patient 20 years post-mastectomy: issues to consider. Breast J 2019;25(6):1067–71.
[16] Brown CR, Jones KT. Incidence of breast cancer in a cohort of 5,135 transgender veterans. Breast Canc Res Treat 2015;148(1):191–8.
[17] Gooren LJ, van Trotsenburg MA, Giltay EJ, van Diest PJ. Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. J Sex Med 2013;10(12):3129–34.
[18] Van Reeseghem SMJ, Van Dorpe J, Monstrey SJ, Defreyne J, Claes K, Pael M, et al. Routine histopathological examination after female-to-male gender-confirming mastectomy. Br J Surg 2018;105(7):885–92.
[19] Baker CM, Pyle ME, Tobias AM, Bartlett RA, Phillips J, Fein-Zachary VJ, et al. Establishing a cohort of transgender men and gender nonconforming individuals to understand the molecular impact of testosterone on breast physiology. Transgend Health 2019;4(1):326–30.
[20] de Blok CJ, Wulf GM, van Engelen K, Adank MA, Dreijerink KM, et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in The Netherlands. Br Med J 2019;365:l1652.
[21] Gooren LJ, Bowers M, Lips P, Konings I. Five new cases of breast cancer in male transsexual persons. Andrologia 2015;47(10):1202–4.
[22] Barghouthi N, Turner J, Perini J. Breast cancer development in a transgender male receiving testosterone therapy. Case Rep Endocrinol 2018;2018:3652602.
[23] Burcombe RJ, Makris A, Pittam M, Finer N. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in The Netherlands. Br Med J 2019;365:l1652.
[24] Gooren L, Bowers M, Lips P, Konings I. Five new cases of breast cancer in transsexual persons. Andrologia 2015;47(10):1202–4.
[25] Baker CM, Pyle ME, Tobias AM, Bartlett RA, Phillips J, Fein-Zachary VJ, et al. Establishing a cohort of transgender men and gender nonconforming individuals to understand the molecular impact of testosterone on breast physiology. Transgend Health 2019;4(1):326–30.
cancer: case reports and review of the literature. Clin Breast Canc 2019;19(1): e12–9.

[26] Fundytus A, Saad N, Logie N, Roldan Urgoiti G. Breast cancer in transgender female-to-male individuals: a case report of androgen receptor-positive breast cancer. Breast J 2020;26(5):1007–12.

[27] Gooren L, Bowers M, Lips P, Konings IR. Five new cases of breast cancer in transgender persons. Andrologia 2015;47(10):1202–5.

[28] Katayama Y, Motoki T, Watanabe S, Miho S, Kimata Y, Matsuoka J, et al. A very rare case of breast cancer in a female-to-male transsexual. Breast Cancer 2016;23(6):939–44.

[29] Light M, McFarlane T, Ives A, Shah B, Lim E, Grossmann M, et al. Testosterone therapy considerations in estrogen, progesterone and androgen receptor positive breast cancer in a transgender male. Clin Endocrinol 2020. https://doi.org/10.1111/cen.14263.

[30] Nikolic DV, Djordjevic ML, Granic M, Nikolic AT, Stanimirovic VV, Zdravkovic D, et al. Importance of revealing a rare case of breast cancer in a female to male transsexual after bilateral mastectomy. World J Surg Oncol 2012;10:280.

[31] Shao T, Grossbard ML, Klein P. Breast cancer in female-to-male transsexuals: two cases with a review of physiology and management. Clin Breast Canc 2011;11(6):417–9.

[32] Tanini S, Fisher AD, Meattini I, Bianchi S, Ristori J, Maggi M, et al. Testosterone and breast cancer in transmen: case reports, review of the literature, and clinical observation. Clin Breast Canc 2019;19(2):e271–5.

[33] Treskova I, Hes O, Bursa V, et al. Importance of revealing a rare case of breast cancer in a female to male transsexual after bilateral mastectomy. World J Surg Oncol 2012;10:280.

[34] McEvenue G, Xu FZ, Cai R, McLean H. Female-to-male gender affirming top surgery: a single surgeon’s 15-year retrospective review and treatment algorithm. Aesthetic Surg J 2018;38(1):49–57.

[35] Monstreyl S, Selvgaggi G, Ceulemans P, Van Landuyt K, Bowman C, Blondeel P, et al. Chest-wall contouring surgery in female-to-male transsexuals: a new algorithm. Plast Reconstr Surg 2008;121(3):849–59.

[36] Li C, Ulrice D, Daling J. Clinical characteristics of different histologic types of breast cancer. Br J Canc 2005;93(9):1046–52.

[37] Secreto G, Zumboff B. Role of androgen excess in the development of estrogen receptor-positive and estrogen receptor-negative breast cancer. Anticancer Res 2012;32(8):3223.

[38] Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: real analysis of nine prospective studies. J Natl Canc Inst 2002;94(8):606–16.

[39] Missmer SA, Elissah AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Canc Inst 2004;96(24):1856–65.

[40] Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biyessy C, et al. Post-menopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Canc 2005;12(4):1071–82.

[41] Dorgan JF, Stanczyk FZ, Kahele LL, Brantin LA. Prospective case-control study of postmenopausal serum estradiol and testosterone levels and breast cancer risk. Breast Canc Res 2010;12(6):R98.

[42] Elissah AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Canc Inst 2006;98(19):1406–15.

[43] Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biyessy C, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Canc Inst 2005;97(10):755–65.

[44] Tworoger SS, Missmer SA, Elissah AH, Spiegelman D, Folkert E, Dowsett M, et al. The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women. Cancer Epidemiol Prev Biomark 2006;15(5):967–71.

[45] Farhat CN, Cummings SR, Chlebowski RT, Parimi N, Cauley JA, Rohan TE, et al. Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. J Natl Canc Inst 2011;103(7):562–70.

[46] Glaser R, Dimitrakakis C. Testosterone and breast cancer prevention. Maturitas 2015;82(3):291–5.

[47] Slager MH, Gooren LJ, Scirpas A, Petrali CD, Diamandis EP. Effects of long-term androgen administration on breast tissue of female-to-male transsexuals. J Histochem Cytochem : Off J Histochem Soc 2006;54(8):305–10.

[48] McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Prev Biomark 2006;15(6):1159–69.

[49] Olsson HL, Olsson ML. The menstrual cycle and risk of breast cancer: a review. Front Oncol 2020;10.

[50] Hubbard RA, Kerlikowske K, Flowers CI, Yankaskas BC, Zhu W, Miglioretti DL. Breast density and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Canc Inst 2016;114(9):619–28.

[51] Bevers T, Havelie M. NCCN guidelines: breast cancer screening and diagnosis. National Comprehensive Cancer Network, version; 2014. p. 1.

[52] Jirtle RL,征求意见稿. Breast cancer screening, management, and a review of case study literature in transgender men. Curr Opin Endocrinol Diabetes Obes 2017;24(3):233–9.

[53] Deutsch MB, Radix A, Wesp L. Breast cancer screening, management, and a review of case study literature in transgender populations. Semin Reprod Med 2017;35(5):343–41.

[54] Preventive health for transgender men and women. In: Imborek KL, Graf EM, McCune K, editors. Seminars in reproductive medicine. Thieme Medical Publishers; 2017.

[55] Deutsch MB, Radix A, Wesp L. Breast cancer screening, management, and a review of case study literature in transgender populations. Semin Reprod Med 2017;35(5):343–41.

[56] Preventive health for transgender men and women. In: Imborek KL, Graf EM, McCune K, editors. Seminars in reproductive medicine. Thieme Medical Publishers; 2017.

[57] Phillips J, Fein-Zachary VJ, Mehta TS, Littlehale N, Venkataraman S, Slanetz PJ. Breast imaging in the transgender patient. Am J Surg 2011;205(5):1149–56.

[58] van Bockstal MR, Monstrey SJ, van Deurzen CH. The role of routine histopathology after chest-contouring surgery in transmen. Eur J Surg Oncol 2015;82(3):291–5.

[59] Nomikos A, Husain EA, Graham AD. Occult disease in reduction mammoplasties and prophylactic mastectomies. Breast J 2020;26(4):691–6.

[60] Oncologie LWD. Borstkanker landelijke richtlijn.